HOME >> BIOLOGY >> NEWS
Vion's TAPET® administered to first patients in Phase I human intratumoral safety trial at the Cleveland Clinic Foundation

NEW HAVEN, CONN., DECEMBER 8, 1999 -- VION PHARMACEUTICALS, INC. (NASDAQ NM: VION) today announced that VNP20009, the company's first generation TAPET® bacterial vector, has been administered to the first patients enrolled into Vion's Phase I intratumoral trial, which is being conducted at The Cleveland Clinic Foundation. The patients were initially monitored in the hospital and subsequently discharged. Potential safety and efficacy will continue to be monitored according to the protocol. The Phase I study is designed to evaluate the safety, potential efficacy and optimum biological dose of an intratumoral administration for patients with either cutaneous or subcutaneous solid tumors. Patients will be evaluated for the accumulation of VNP20009 in the tumor and non-injected lesions. Patient accrual continues for this trial, which may involve up to 20-30 patients.

TAPET (Tumor Amplified Protein Expression Therapy), Vion's core platform technology, are highly attenuated bacteria that, in preclinical studies, have demonstrated preferential replication in tumors compared to normal tissues. The bioengineered bacteria have demonstrated an excellent safety profile in preclinical toxicology studies. Preferential replication allows the bacteria to produce and deliver a variety of anti-cancer therapeutic products at high concentrations to tumors while minimizing toxicity to normal tissues. By bringing the "drug factory" preferentially to the tumor, Vion believes that TAPET may result in a cancer therapy that is more concentrated, more effective and less toxic to normal tissue. Furthermore, the unarmed bacteria by themselves have shown good anti-tumor activity in animal models. Vion plans to develop the unarmed TAPET alone as an anti-tumor agent and to develop second-generation products that produce and deliver potent therapeutic anti-cancer agents.

Vion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the research, development and commerci
'"/>

Contact: Sue Yeoh
syeoh@cpronline.com
201-641-2408 x43
Vion Pharmaceuticals, Inc.
8-Dec-1999


Page: 1 2

Related biology news :

1. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
2. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
3. Newly identified master gene key in babys first breath
4. The book opens on the first tree genome
5. DuPont developing new protective suits for military, first responders
6. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
7. Maine-based biophysics institute gets funding for first US-based 4Pi nanoscale microscope
8. Veterinarians discover first known case of canine distemper in a wild tiger
9. Study reveals first genetic step necessary for prostate cancer growth
10. The first engineering of cell surfaces in living animals
11. Infant rats eagerly accept high concentrations of alcohol upon first exposure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: